Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
AC Immune SA (ACIU) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2,68, with a market capitalisation of $264,48M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,10 to $4,00. This page covers its latest market performance, valuation, price trends and company information.
$264,48M | |
$2,68 | |
$19,97 | |
$1,43 | |
$2,68 | |
100,00 | |
220,22K | |
-- | |
$4,00 | |
$2,10 | |
-- | |
-- |
AC Immune SA (ACIU) is trading at $2,68 in pre-market trading as of 2026-09-16 08:27:00, down 0,19% ($0,01) from the previous close of $2,68
Pre-market trading shows how investors are pricing ACIU before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, AC Immune SA (ACIU) moved from $2,86 to $2,68, representing a decline of 6,47% ($0,19).
The stock traded between $2,59 and $2,94 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 124,48 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 30,4%
ACIU is currently trading at $2,68, placing it 30,4% of the way from its 52-week low of $2,10 to its 52-week high of $4,00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
| Employees | 122 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AC Immune SA (ACIU) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.